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Summary.-The effect has been studied of adding either misonidazole (MISO) or
metronidazole (METRO) to cytotoxic drug treatment of C3H mice bearing the
RIF-1 sarcoma. The nitroimidazoles were injected 30 min before the cytotoxic drugs
at a dose of 2'5 mmol/kg. Both clonogenic-cell survival and growth delay were
measured as indicators of tumour response and depression in WBC count and acute
lethality were used to indicate normal-tissue response. For melphalan, neither
pretreatment agent produced any change intumour response. For cyclophosphamide,
no change was produced by METRO but a minimal increase in tumour response
occurred with MISO. An enhancement of cell killing by CCNU was seen with MISO
pretreatment, but there was no increase in tumour growth delay. METRO, however,
did not enhance tumour response by either endpoint. WBC depression by CCNU
was not enhanced by MISO pretreatment, and there was no significant reduction in
the acute LD50. This indicates a therapeutic advantage from the addition of MISO
to CCNU in this model system. For chlorambucil, considerable enhancement of
tumour response followed either MISO or METRO pretreatment (dose-modifying
factors of 2.0 and 1*4 respectively). However, the modification by MISO of normal-
tissue response to chlorambucil was also enhanced by about a factor of 2, with no
therapeutic gain.
SEVERAL RECENT STUDIES have demon-
strated that tumour response to cytotoxic
drugs in mice can be enhanced by the
2-nitroimidazole misonidazole (MISO), a
radiosensitizer ofhypoxic cells (Rose et al.,
1980; Clement et al., 1980; Tannock,
1980a, b; Siemann, 1981, 1982; Twenty-
man, 1981; Law etal., 1981; Mulcahy etal.,
1981; Martin et al., 1981; Clutterbuck et
al., 1982; Stephens et al., 1981). In some of
these studies (but not all) a therapeutic
gain is claimed, in that enhancement of
tumour response is greater than enhance-
ment of normal-tissue damage.
Using the RIF-1 sarcoma in C3H mice,
we have recently found that tumour
growth delay induced by cyclophospha-
mide is considerably enhanced by the
simultaneous administration of 5 mmol/
kg (1 mg/g) MISO. At lower doses of
MISO, however, much of the effect is lost
(Twentyman, 1981).
In this paper, we describe experiments
using the RIF-1 sarcoma in which we have
studied the enhancement of a number of
cytotoxic drugs by both MISO and the
less electron-affinic 5-nitroimidazole
analogue, metronidazole (METRO). The
cytotoxic drugs studied were the nitrogen
mustards, cyclophosphamide (CTX), mel-
phalan (MEL) and chlorambucil (CHL),
and the nitrosourea CCNU. Both growth
delay and survival of clonogenic cells
have been used as measures of tumour
response. Depression of white blood cell
(WBC) count and lethality have also been
studied as indicators of normal-tissue
response.P. TWENTYMIAN AND P. WORKMAN
MATERIALS AND METHODS
Mice and tumours.-The mice used in these
studies were inbred C3H/He supplied by
OLAC. Both male and female mice were
used in different experiments, without any
apparent differences in tumour growth rate
or therapeutic response. Mice entered experi-
ments at the age of 12-16 weeks and weighed
20-28 g.
Details of the RIF-1 mouse sarcoma have
been previously described (Twentyman et al.,
1980), as have the methods used for tumour-
cell inoculation into the gastrocnemius muscle
ofthe hind limb, the subsequent measurement
of tumour growth, and the conversion of leg
measurements to tumour weight (Twentyman
et al., 1979). The endpoint of growth delay
was calculated from the time taken for
individual tumours to reach 4 x the initial
group-mean treatment volume. In these
experiments, tumours were 300-600 mg at the
time of treatment and 9-12 mice were used
in each treatment group.
Cell survival acssay.-Twenty-four hour-s
after drug treatment, mice were killed and the
RIF-1 tumours were excised from the hind
legs. Pooled tumour material from 2 identi-
cally treated mice w%as used to assay cell
survival at each treatment point. The
tumours were weighed and minced finely
with scissors. The resulting brei was then
agitated for 45 min in a solution of 1 mg/ml
ofneutral protease (Type IX, Sigma Chemical
Co.) (Twentyman & Yuhas, 1980) in complete
culture medium (see below). The suspension
was then filtered through cotton gauze,
centrifuged for 5 min at 200 g, and resus-
pended in complete medium. Cell counts were
carried out using a haemacytometer, appro-
priate dilutions were made, and cells plated
out into 9cm-diameter Petri dishes (Sterilin)
in 11 ml of complete medium. Dishes were
incubated for 13 days at 37°C in an atmos-
phere of 500 CO2 and 95% air. The dishes
were then fixed and stained with crystal
violet. Colonies of > 50 cells were then
counted.
The culture medium used was Eagle's
mninimal essential medium with the addition
of 2000 new-born calf serum (both Gibco
Biocult). The cell yield was generally in the
region of 1-2 x 108 cell/g of tumour, and the
plating efficiency of cells from untreated
tumours was 15-45%
White cell counts. A scalpel was used to
cut a fewr mm from the tip of the tail of
unanaesthetized mice. A capillary pipette
was then used to draw up 0-02 ml of blood,
which was diluted in 20 ml of "Isoton"
(Coulter Electronics Ltd.). Six drops of
"Zapoglobin" were added to lyse the red
cells, and counts were made on an electronic
particle counter (Coulter Electronics-Model
ZB1).
Drugs. Misonidazole (MISO) and metron-
idazole (METRO) were kindly supplied by
Dr Carey Smithen ofRoche Products Ltd and
by May & Baker Ltd respectively. They were
dissolved in Hanks' balanced salt solution
(HBSS) and injected i.p. in a volume of
0-04 ml/g to give a dose of 2-5 mmol/kg
(=500 mg/kg for MISO and 428 mg/kg for
METRO). Cytotoxic drugs were obtained and
prepared as shown in Table I. All drugs were
freshly prepared immediately before admini-
stration and injected i.p. Control mice
received appropriate volumes of HBSS and/
or cytotoxic drug vehicles. MISO andMETRO
were administered 30 min before the cytotoxic
drugs. This interval was chosen as it corre-
sponds to the peak of the plasma-concentra-
tion curves after i.p. administration (Work-
man, unpublished) and also lies within the
range of times found to be optimal for CTX
in combination with 3-75 or 5 mmol/kg of
MISO (Twentyman, 1981; Law et al., 1981).
RESULTS
Melphalan
The effect of MISO or METRO pre-
treatment on cell survival after MEL is
shown in Fig. 1. The points for mice
receiving sensitizers are scattered around
the line drawn through the points for MEL
alone; hence there is no evident enhance-
ment oftumour response at MEL doses up
to and beyond the acute LD50s125 mg/
kg. Similarly the growth delay (Table II)
indicates little if any enhancement by
MISO.
Cyclophosphamide
The cell-survival data for CTX are
shown in Fig. 2. The solid line is drawn by
eye to fit the points for CTX alone. There
is a tendency for the points for mice
receiving MISO to be below the solid line,
and this trend is indicated by the broken
line. The effect is, however, small and not
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TABLE I.-Cytotoxic drugs: Preparation and administration
Drug
Cyclophosphamide
(CTX)
Melphalan
(MEL)
1-(2-Chloroethyl)-3-
cyclohexyl-1-nitro-
sourea (CCNU)
Chlorambucil
(CHL)
Supplier
Ward Blenkin-
sop Ltd
Chester Beatty
Research
Institute
U.S. National
Cancer
Institute
Chester Beatty
Research
Institute
Preparation
Dissolve in HBSS
Dissolve in acidified ethanol.
Dilute 1:10 in propylene glycol-
K2HPO4 buffer, final pH 7-4
Dissolve in absolute ethanol.
Dilute 1:20 in 0.5% carboxy-
methyl cellulose/Hanks'
Dissolve in absolute ethanol.
Dilute 1:10 in arachis oil B.P.
Administered volume
(ml/g)
0-005-0 -02
0-01
0*005-0*05
0*01
(mg/kg)
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FIG. 1.-Change in surviving fraction of
RIF- 1 tumour cells treated in vivo with
dose of melphalan and assayed 24 h later.
Closed symbols-MEL alone. Open sym-
bols-pretreatment with MISO (2.5 mmol/
kg) 30 min before MEL. Half-closed sym-
bols-pretreatment with METRO (2-5
mmol/kg) 30 min before melphalan. Differ-
ent shapes of symbols indicate different
experiments. The solid line is drawn by eye
to fit the solid symbols.
measured below 10-4 using these tech-
niques. There is no effect with METRO.
Our previously published growth-delay
data for CTX (Twentyman, 1981) are in
agreement with the MISO result, showing
(at a MISO dose of 1P65 or 3-35 mmol/kg)
a small additional growth delay, but not
dependent on dose of CTX.
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dose-dependent up to 150 mg/kg. Al-
though the acute LD50 for CTX in our
mice is 250 mg/kg, higher doses were not
used because cell survival cannot be
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FiG. 2.-As Fig. 1, for cyclophsophamide. The
broken line indicates a trend for the open
symbols (MISO pretreatment) to lie below
the corresponding solid symbols.
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TABLE II.-Growth delay in the RIF-1 tumour induced by cytotoxic drugs with or without
misonidazole (2.5 mmol/kg)
Drug Expt
MEL 1
2
CCNU
CHL
1
2
3
1
2
3
Dose
(mg/kg)
10
7-5
10
30
30
40
50
10
10
7.5
15
Growth delay*
(days)
-MISO +MISO
5-9 (2.2) 5-3 (1-2)
1-8 (0-6) 2-2 (0.9)
4-2 (0.9) 6-1 (1*1)
0-6 (1-6) 2-0 (1-6)
4-4 (1*6) 5-2 (1.0)
4-8 (3.2) 4*9 (1-5)
6*1 (2.5) 6 5 (3.4)
4-3 (1-6) 9-8 (0.4)
4-9(1.1) 9-9(1-4)
2.3 (1-3) 5-7 (1.1)
5*1 (1-2)
* Values are means for groups of 8-10 mice. Figures
in brackets are 2 x s.e.
--NU are fitted by the broken line. At doses up
Cell-survival data for CCNU are shown to 30 mg/kg, there is a considerable
Fig. 3. The solid line is drawn by eye to spread in the data but, in general, the
the solid symbols (CCNU alone), where- points for MISO pretreatment lie below
the open symbols (MISO pretreatment) those for CCNU alone. Above 30 mg/kg,
the enhancement is much clearer, with
about 10 x more killing with MISO Dose (mg/kg) pretreatment at 60 mg/kg. For a survival
'100 15 30 45 6 f1 0°° 1 30 45 60 Of 10-2, the DMF is 1-3-1*4. For METRO
A <* v CCNU pretreatment there is no difference at any T V dose from the points for CCNU alone.
0 \ Growth-delay data are shown in Table II.
A \ It may be seen that even at high doses of
v CCNU there is no significant increase in
10 * growth delay with MISO pretreatment.
This may be due to the intrinsic lack of
v, the growth-delay assay for a drug such
\\. as CCNU where a compensating rapid I
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TABLE III.-Enhancement of CCNU res-
ponse of the RIF-1 tumour by 5 mmol/kg
MISO*
CCNU
dose
(mg/kg)
15
30
45
Growth delayt (days)
-MISO +MISO
0*1(06) 1*6(1*1)
1-0(0-6) 4-8(1-1)
4.0 (1.4) 8-6T
FIG. 3.-As Fig. 1, for CCNU. The broken
line is drawn by eye to fit the open symbols
(MISO pretreatment).
* MISO alone at this dose has been previously
shown to have no effect on growth delay.
t Values shown are means forgroups of 7-10 mice.
Figures in brackets are 2- s.e.
$ Only 2 mice out of 7 survived in this group.
The value given is the mean of the 2 individual
values of 7-4 and 9 9.
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TABLE IV.-Determinations of LD50 values for CCNU and CHL in the presence or
absence of MISO (2.5 mrnol/kg)
LD50 (95% confidence limits)*
(mg/kg)
Drug Experiment
CCNU A
B
C
A+B+C
combineCl
CHL
-MISO
76 2 (53 - 4-108 - 8)
64 - 0 (56 5-72 -5)
67 0 (59 - 0-76 - 1)
66-3 (61-3-71-6)
A 25 - 3 (23 8-26 9)
B 27-4 (t)
+MISO
92-4 (77-5-110-0)
54 - 8 (31-6-95-1)
52-6 (46-0-60-2)
60-5 (54-5-67-1)
14-9 (14-3-15-6)
14-8 (13-3-16-5)
DMF (95% CL)
0 82 (0-55-1-27)
1-17 (0.66-2.05)
1-27 (1-06-1-53)
1.10 (0-96-1-25)
1 -70 (1-58-1-83)
1-85 (t)
* Determined 30 days after drug administration, using the GLIM computer programme for
probit analysis.
t The survival fell from 1000% to 00% at adjacent drug doses, henCe no estimate ofconfidence
limits.
Dose (mg/kg)
5 10
Chlora
The result of an earlier growth-delay
15 20 experiment in which 5 mmol/kg MISO
imbucil was given simultaneously with CCNU to mice bearing the RIF-1 sarcoma is shown
in Table III. At this higher dose ofMISO,
a clear enhancement is seen at 30 mg/kg
of CCNU, though there is also increased
toxicity.
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FIG. 4. As Fig. 1, for chlorambucil. The
lower broken line is drawn by eye to fit the
open symbols (AIISO pretreatment). The
upper broken line is drawn by eye to fit the
half-closed symbols (AMETRO pretreat-
ment.)
regeneration of surviving clonogenic cells
persist to several times the treatment
volume as has been previously reported
in the B16 melanoma (Stephens &
Peacock, 1977).
10o
5 {
0 10 30
Dose (mg/kg)
FiG. 5.-Total WBC count 3 days after
CCNU. Closed symbols CCNU alone.
Open symbols pretreatment with MISO
(2-5 mmol/kg) 30 min before CCNU. 0,
and A A are separate experiments. Points
are mean values for group of 5 mice. Error
bars show + 2 x s.e.
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Determinations of the LD50 of CCNU
with and without MISO are shown in
Table IV. Three separate experiments gave
a range of DMFs with wide confidence
limits. The data have therefore been
combined to calculate an overall DMF of
1l10. WBC counts are shown in Fig. 5.
It may be seen that at the nadir on Day 3
no enhancement is produced by the addi-
tion of MISO to CCNU. The counts were
followed for 15 days after treatment, and
the recovery patterns for a given CCNU
dose were also unaffected by MISO pre-
treatment. Delayed myelosuppression is
the dose-limiting toxicity for CCNU in
man, and it should therefore be noted that
these mouse experiments may not be
strictly relevant to the clinical problem.
Chlo-ainbucil
The cell-survival data for CHL are
shown in Fig. 4. Clear enhancement of the
response to this agent is seen for both
MISO and METRO pretreatment. As all 3
lines are approximately exponential, pass-
ing through the origin, it is possible to
estimate DMFs of 1-3-1-4 for METRO
and 2-0 for MISO. This degree of enhance-
ment by MISO pretreatment is confirmed
by the growth-delay data in Table II. In
each of 3 experiments, more than doubling
of the CHL growth delay was brought
about by MISO pretreatment, and from
the third experiment a DMF of -2 was
obtained.
Values of the LD50 for CHL with or
without MISO are shown in Table IV.
In 2 experiments, the DMFs are 1'70 and
1.95. WBC counts are shown in Fig. 6;
they are combined data from 3 experi-
ments. In 2 of the experiments a small
depression in WBC count was caused by
MISO alone. In the third experiment there
was no such initial depression, but the
curves clearly separated with increasing
CHL dose up to 9 mg/kg. From the
combined data a DMF of 2-2 is calcu-
lated from the ratio of CHL doses to halve
the initial count with and without MISO
pretreatment. There is a levelling-off of
E
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FIG. 6.- Total WBC count 3 days after CHL.
Closed symbols-CHL alone. Open sym-
bols pretreatment with MISO (2-5 mmol/
kg) 30 min before CHL. The points are
means for 15 mice combined from 3 separ-
ate experiments (except CHL alone at 15,
20, 25 mg/kg: 5 mice from one experiment).
Error bars show +2 x s.e.
the counts at higher doses, presumably
because of a CHL-resistant fraction of
WBC.
DISCUSSION
In these experiments we have used a
lower dose (2.5 mmol/kg) of MISO than
than has been used in most of the pre-
viously reported studies ofradiosensitizer/
cytotoxic drug combinations. In our mice,
a MISO dose of 5 mmol/kg produces a
drop in body temperature of 5-6°C, per-
sisting for 10-12 h. We feel that such a
profound effect on body temperature may
well complicate the analysis ofresponse to
subsequently administered cytotoxic drugs
by interfering with drug metabolism. At
2*5 mmol/kg, however, the drop in body
temperature is not more than 1 °C for less
than 3 h, and any such problems will
therefore be largely eliminated. It should
also be pointed out that a dose of 2-5
mmol/kg still produces plasma levels of
MISO which are many times higher than
0
E aX
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those obtainable in the clinic. The longer
sensitizer half-life in man may, however,
compensate for the reduced plasma levels,
and preliminary experimental data indi-
cate that prolonged pre-exposure to MISO
can give greater chemosensitization than
an appropriately-timed single dose (Work-
man & Twentyman, unpublished; Dr
J. M. Brown, personal communication). It
should also, of course, be borne in mind
that although we chose (on a rational
basis) to give the sensitizers 30 min before
the cytotoxic drugs, this timing would not
necessarily be best in the clinic. Our
results cannot, therefore, be interpreted in
terms of direct clinical applicability, but
rather as indications of which drug com-
binations should receive priority for study
in an experimental protocol designed to
reproduce clinical pharmacokinetics.
Melphalan
Our result for this drug is in dramatic
contrast to other reported data. In their
original study in the Lewis lung tumour,
Rose et al. (1980) obtained a DMF of 2-0
for clonogenic cell survival on addition of
5 mmol/kg of MISO and, more recently,
Stephens et al. (1981) have found a
similar factor at a lower MISO dose of
3.75 mmol/kg in the same system. The
same workers also found a DMF of 1-9 for
MEL with the addition of 5 mmol/kg of
MISO in the HX32 human pancreatic
carcinoma xenograft. In a study by
Clutterbuck et al. (1981) the growth delay
induced by MEL in 2 human melanoma
xenografts was clearly enhanced by 5
mmol/kg of MISO, though no DMF could
be estimated from the data. Unpublished
results for the KHT sarcoma, however,
using clonogenic cell survival as the end-
point (Dr D. W. Siemann, personal
communication) show a DMF of only 1-4
when 5 mmol/kg of MISO is added to
MEL. Our finding of no enhancement by
by MISO (2.5 mmol/kg) of the response
of the RIF-1 tumour to MEL is the only
negative result reported to date. We also
have, however, unpublished growth-delay
data for the KHT and EMT6 mouse
30
tumours, which show little if any en-
hancement of MEL by 2-5 mmol/kg of
MISO.
Cyclophosphamide
In the study of Clement et al. (1980) the
effect of CTX against the M5076 ovarian
carcinoma and Lewis lung carcinoma was
enhanced by MISO (3 or 5 mmol/kg) but
the effect against the early B16 melanoma
was not changed. Enhancement of CTX
by MISO (5 mmol/kg) was also seen in the
KHT sarcoma and 16/C carcinoma by
Tannock (1980b). A DMF of 2-2 was
obtained by combining 5 mmol/kg of
MISO with CTX in the Lewis lung tumour
(Rose et al., 1980) and more recently,
Stephens et al. (1981) have reported
DMFs of 2 0 and 2-6 for this same combin-
ation in the Lewis lung tumour and HX32
xenograft respectively. In our own pre-
vious study (Twentyman, 1981) and a
similar study by Law et al. (1981), both
using the RIF-1 mouse tumour, a DMF of
2-0 was found for MISO (5 mmol/kg) in
combination with low doses of CTX
(below 60 mg/kg). At higher CTX doses,
however, the DMF was greatly reduced.
We also found that the effect in this
tumour was much reduced at lower doses
of MISO.
A relatively small DMF of , 1-4 for
CTX with 5 mmol/kg MISO was, how-
ever, found in the KHT tumour by Dr
D. W. Siemann (personal communication)
and this agrees with our finding of only a
small enhancement in this tumour
(Twentyman, 1981).
Clearly the enhancing effect ofMISO on
CTX is very variable. Although most
tumours show an enhancement at a MISO
dose of 5 mmol/kg, the effect may be lost
with lower doses, and in the RIF-1
tumour is barely significant at 2-5 mmol/
kg.
CCNU
Interaction between CCNU and MISO
has been extensively studied by Siemann
(1981, 1982). He demonstrated that, in the
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KHT sarcoma, a DMF of 2.0 could be
obtained with 5 mmol/kg of MISO, and
that only a small reduction in the DMF
was caused by reducing the MISO dose to
2-5 mmol/kg. Normal tissue toxicity of
CCNU (assessed in an LD50 assay) was
enhanced by DMFs of only 1P14 and 1-36
at 2-5 and 5 mmol/kg of MISO, however,
and CCNU-induced depression of WBC
count was enhanced by a factor of 1 1-1P4.
There was, therefore, a clear therapeutic
gain. In the RIF-1 tumour the DMF was
2.0 for 5 mmol/kg of MISO, and in the
MT-1 mammary tumour the DMF was
1P5 at 2-5 mmol/kg of MISO (Siemann,
1982). In the study by Stephens et al.
(1981) a MISO dose of 3-75 mmol/kg
enhanced the CCNU response of the Lewis
lung tumour by a factor of 1P5. Our results
presented in this paper indicate that there
is a partial loss of enhancement in the
RIF-1 tumour when the MISO dose is
reduced from 5 to 2-5 mmol/kg. At higher
CCNU doses, however, the enhancement
is still significant, and the minimal
increase in normal-tissue toxicity at this
dose of MISO means that the combina-
tion is therapeutically advantageous in
our system. Our findings of no enhance-
ment of CCNU by METRO is in contrast
to our result in the KHT sarcoma, where
METRO at 2-5 mmol/kg produces a simi-
lar DMF to MISO at the same dose level
(Workman & Twentyman, submitted).
Chlorambucil
We are not aware of any other data for
the combination of radiosensitizers with
this agent. In this study, the DMFs for
CHL in combination with MISO or
METRO are larger than for any of the
other agents (i.e., 2-0 and 1-4 respec-
tively). We have obtained a similar factor
for MISO and CHL in the KHT and
EMT6 tumours (unpublished). In contrast
to almost all other results in the literature,
however, the enhancement of CHL in
terms of whole-body toxicity (i.e., LD50)
is as great as the enhancement against the
tumour. In these experiments mice dying
from either CHL alone or from CHL+
MISO did so within 24 h of drug adminis-
tration. This is also true of mice dying
from very large doses of MISO alone, and
it is not therefore possible to separate out
the 2 components of the lethal effect. It
would appear, however, that when ani-
mals die so rapidly, the cause of death is
not cytotoxicity by conventional alkyla-
tion mechanisms. In this respect, there-
fore, enhancement of CHL toxicity by
MISO is different in nature to that seen for
other alkylating agents. However, the
depression of WBC count (measured at
Day 3) by CHL is also enhanced by MISO
to the same extent as whole-body lethality,
and this endpoint presumably reflects the
cytotoxicity of CHL to WBC precursors
in the marrow. The fact that MISO pre-
treatment enhances these 2 different
mechanisms of toxicity would perhaps
suggest that enhancement takes place via
a non-specific modification of CHL phar-
macokinetics.
Summarizing, these results indicate that
in the RIF-1 tumour little or no enhance-
ment of tumour response is produced by
adding MISO (2.5 mmol/kg) to MEL or
CTX. Enhancement of CCNU is seen at
higher drug doses and is greater in the
tumour response than in normal-tissue
toxicity. For CHL, large DMFs are
obtained, but these are as large for normal
tissues as they are for the RIF-1 tumour,
so this combination produces no thera-
peutic gain.
METRO is clearly less active than
equimolar MISO in combination with the
cytotoxic drugs investigated here. We are
currently involved in a detailed study of
the effect of electron affinity and lipo-
Dhilicity of nitroimidazoles on sensitiza-
tion to various cytotoxic agents. Pre-
liminary studies have revealed a number
of analogues more active than MISO in
combination with CCNU.
These data, taken together with data
reported by others, confirm the very
variable nature of drug enhancement by
radiosensitizers. Mechanistic studies are
urgently required to elucidate the nature
ofthe interaction.
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